Sanity Group
AcquiredBerlin, DE · Founded 2018 · 110 employees on LinkedIn · 16 known investors
Sanity Group manufactures and distributes cannabinoid-based pharmaceutical products under the avaay Medical brand across European markets, including medical cannabis. The company operates in the medical cannabis and pharmaceutical sector, with a focus on patient access to cannabis-based therapeutics.
Also known as Sanity Group GmbH
Investors · 16
Also in the syndicate · 9
Company profile
researched Aug 2026Sanity Group GmbH is a Berlin-headquartered cannabis company founded in 2018 by Finn Age Hänsel and Fabian Friede. It operates across three pillars: Sanity Medical (development and distribution of cannabis-based pharmaceuticals to pharmacies and clinical institutions through the Vayamed and avaay Medical brands, plus Endosane Pharmaceuticals for finished pharmaceuticals and Belfry Medical for medical devices and digital health applications), Sanity Care (consumer products based on non-psychoactive cannabinoids under the VAAY wellbeing brand and This Place natural cosmetics), and Sanity Science (R&D projects and production of cannabis extracts for the group's business areas). The company operates a production and processing facility for cannabis extracts near Frankfurt am Main alongside its Berlin headquarters.
The group describes its structure as closer to a distributor and brand house than a vertically integrated North American licensed producer: it sources cultivated flower from licensed producers and concentrates on importation, GMP-compliant handling, pharmacy supply and brand building. Beyond Germany, its footprint includes Switzerland, the United Kingdom, Poland and Czechia, and it participates in Swiss federally authorised pilot trials of regulated adult-use cannabis sales conducted under Article 8a of the Swiss Narcotics Act.
In February 2026 Organigram Global Inc. entered a share purchase agreement to acquire the shares of Sanity Group it did not already hold; the transaction closed in April 2026 and by August 2026 Sanity Group was being integrated into Organigram's global corporate structure, with founder Finn Hänsel appointed Chief Strategy Officer & President, Rest of World and Adrian Frenzel becoming Organigram's Global Chief Operating Officer.
Founding story
The company was founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede. Hänsel had five years of consulting experience in consumer goods, insurance and pharma and previously founded five companies including THE ICONIC, Berliner Berg Craft Beer, Sportsecondhand, Valmano and Petobel; Friede had nine years building businesses and leading international teams in marketplaces, eCommerce and tech and had founded three companies. The stated goal was to unlock the health benefits of cannabinoids and make them accessible in Europe.
Business model
Sanity Group develops and distributes cannabinoid-based pharmaceuticals, medical devices and digital applications to pharmacies and clinical institutions, and sells CBD-based wellbeing and cosmetics products to consumers through e-commerce and retail. It sources cannabis flower from licensed producers and focuses on importation, EU-GMP-compliant handling, pharmacy supply, brand building and extract production at its own facility near Frankfurt am Main.
Revenue derives from sales of prescription medical cannabis flower and extracts distributed to pharmacies and clinical institutions, from consumer CBD products (oils, sprays, capsules, topicals, bath products) sold online and via retail, and from participation in regulated recreational pilot programs.
Traction
Around 120 employees across medical, consumer health and science units as of 2022, with over 120 staff reported at the Berlin headquarters and the Frankfurt-area extraction plant. Total funds raised exceeded $100 million by September 2022. In the quarter reported in August 2026, Sanity Group contributed approximately CAD 40 million, or 35 percent, of Organigram's consolidated net revenue and was accretive to adjusted EBITDA; quarterly revenue rose 34 percent over two calendar quarters to €25.5 million.
Latest developments
In April 2026 Organigram closed its acquisition of Sanity Group for €107.3 million upfront (€78.0 million cash and €29.3 million in shares), with up to €113.8 million of earnout tied to performance through April 1, 2027; Max Konrad Narr joined Organigram's board for the earnout period. In June 2026 Sanity Group announced a partnership with Bogen Pharma GmbH, a subsidiary of Astrasana Holding AG, to supply avaay Medical cannabinoid medicines in Switzerland. In August 2026 Organigram announced accelerated integration of Sanity Group, with Finn Hänsel becoming Chief Strategy Officer & President, Rest of World and Adrian Frenzel becoming Global Chief Operating Officer.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Described as one of Germany's and Europe's leading cannabis companies and, per Organigram, one of Europe's leading pure-play cannabis operators with a scalable European platform. It is frequently cited in German business press as a leading domestic cannabis startup. Claims about its share of the German medical cannabis market (often cited as around 10%) are company-reported rather than regulator-published, and market share, revenue and patient-count figures circulating publicly are largely self-reported.
A multi-brand structure spanning medical cannabis, finished pharmaceuticals, medical devices/digital health and consumer CBD under one group; in-house extract production; regulatory expertise across multiple European jurisdictions; and medical and political advisory boards of clinicians, pharmacologists and former government and insurance figures.
Technology
Activities span cannabis extract production and processing at a facility near Frankfurt am Main, research and development on finished pharmaceuticals, new dosage forms, medical devices and digital health applications (via Belfry Medical), and clinical research collaborations on cannabinoid-based therapies.
Go-to-market
Medical products reach patients only via prescription through licensed pharmacies, supported by physician education, a medical advisory board of pain, palliative, neurology and pharmacology specialists, and distribution partnerships such as the agreement with Bogen Pharma GmbH (Astrasana Holding AG) in Switzerland. Consumer CBD products are sold through e-commerce and retail channels. The company also engages publicly in cannabis policy debate and industry associations.
German and other European pharmacies, clinical institutions and prescribing physicians serving medical cannabis patients; consumers of CBD wellbeing and cosmetics products across several European countries.
Geography
Headquarters in Berlin with an extraction/production facility near Frankfurt am Main. Operations and expansion cover Germany, Switzerland, the United Kingdom, Poland and Czechia; following integration, the combined Organigram supply and commercial network spans Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia.
History
Founded in 2018 in Berlin, Sanity Group built a portfolio of subsidiaries and brands covering medical cannabis (Vayamed, avaay Medical), finished pharmaceuticals (Endosane), medical devices and digital applications (Belfry Medical), wellbeing (VAAY) and natural cosmetics (This Place), and added an extract production facility near Frankfurt am Main. Redalpine led a Series A in 2021, the same year Canadian producer Organigram Holdings disclosed a minority equity investment. A $37.6 million Series B led by BAT Group followed in September 2022. Reporting indicates the company navigated declining sector valuations and tighter capital markets after 2022, including restructuring and headcount reductions reported in early 2024, and raised a reported €17 million in June 2024. Organigram agreed to acquire the remaining shares under a February 18, 2026 share purchase agreement, closing in April 2026, followed by integration into Organigram's corporate structure in August 2026.
Risks & controversies
Publicly circulating market-share, revenue and patient figures are company-reported and not independently verifiable against regulator statistics, including the frequently cited ~10% share of the German medical cannabis market. CBD ingestible products face unresolved EU novel-food status and member-state-specific rules, and EU and national rules restrict health claims on CBD products. The Swiss adult-use activities are time-limited research pilots rather than a permanent legal market, and German law permits only medical commercial sales, with non-commercial adult-use possession, home cultivation and cultivation associations introduced under the 2024 Cannabis Act. The company has navigated falling sector valuations since 2022 with reported restructuring and layoffs.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 6
launches, deals, and filingsOrganigram announced accelerated integration of Sanity Group into its global corporate structure. Sanity founder Finn Hänsel was appointed Chief Strategy Officer & President, Rest of World; Adrian Frenzel became Global Chief Operating Officer; Tim Emberg remained President, Canada. The combined supply and commercial network spans Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia.
Sanity Group announced a partnership with Bogen Pharma GmbH, a subsidiary of Astrasana Holding AG, to strengthen patient supply of avaay Medical cannabinoid-based medicines in Switzerland and expand its Swiss medical cannabis activities.
A wholly owned subsidiary of Organigram Global Inc. acquired all issued and outstanding Sanity Group shares not already owned for upfront consideration of €107.3 million, comprising €78.0 million in cash and €29.3 million in share consideration (3,146,195 common shares to sellers and 12,638,228 non-voting Class A convertible preferred shares to BAT at €1.8547/C$3.00 per share), with up to €113.8 million of additional earnout consideration (up to €20.0 million cash and up to €93.8 million in shares) contingent on Sanity Group's performance in the 12 months ended April 1, 2027. Max Konrad Narr was appointed to Organigram's board for the earnout period. The company announced closing on April 16, 2026.
Organigram Global Inc. and Sanity Group entered into a share purchase agreement dated February 18, 2026 for the acquisition of all Sanity Group shares not already owned by Organigram.
Sanity Group announced a $37.6 million Series B round led by BAT Group (via BT DE Investments Inc.), with continued participation from existing investors Redalpine and Casa Verde Capital, described by the company as Europe's largest cannabis investment round to date and bringing total funds raised to over $100 million.
$37.6M source ↗
Canadian licensed producer Organigram Holdings disclosed a minority equity investment in Sanity Group in 2021; the stake was a minority position and Sanity Group continued to operate independently with its own management.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Sanity Groupsanitygroup.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Sanity Group do?
- Berlin-based cannabis company producing medical cannabis and CBD wellbeing brands in Europe, acquired by Organigram Global in 2026.
- Who are Sanity Group's investors?
- Sanity Group's investors include Casa Verde Capital, Cherry Ventures, FoodLabs, German Media Pool, Simon Capital, Tq Ventures Llc, redalpine.
- Where is Sanity Group headquartered?
- Sanity Group is headquartered in Berlin, DE.